Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation

Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatm...

Full description

Bibliographic Details
Main Authors: Gang Shen, Lei Shi, Xin Tian, Depei Huang, Hao Chen, Chan Gao, Xudong Shen, Hushan Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Pharmacology
Subjects:
NSCLC-lung adenocarcinoma-EGFR-ALK-BRAF-KRAS-RET-MET-PD-L1-ROS1.
EGFR
TKI-tyrosine kinase inhibitor
almonertinib
L718Q
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.731895/full
Description
Summary:Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatment option. Herein, we report a patient with metastatic NSCLC who benefited from almonertinib after developing resistance to osimertinib.
ISSN:1663-9812

Similar Items